Status:
UNKNOWN
99mTc-CNDG Injection in the Diagnosis of Malignant Tumors
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Malignant Tumor
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Currently, 18F-fluorodeoxyglucose (18F-FDG) is the most widely used tumor imaging agent in clinical practice. However, the production of 18F requires accelerators and is associated with relatively hig...
Eligibility Criteria
Inclusion
- 18-70 years old
- Patients diagnosed with malignant glioma, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, or other malignant tumors through imaging techniques such as MRI, CT, and ultrasound, and who are scheduled for surgical resection or biopsy
- Solid tumor sizes greater than 2cm
- Voluntarily agree to participate and sign an informed consent form
- Can provide complete surgical records, pathological results, control data, and clinical follow-up results
Exclusion
- Pre-treatment such as chemotherapy and targeted therapy has been administered
- Pregnancy and breastfeeding
- Claustrophobia
- The condition is severe and difficult to cooperate with
- Unable to obtain relevant control imaging data and clinical information
Key Trial Info
Start Date :
August 11 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06030817
Start Date
August 11 2023
End Date
December 31 2025
Last Update
September 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730